OBJECTIVE: To probe into the cost-effectiveness of 3 different therapeutic schemes in the treatment of antituberculosis drug-induced hepatotoxicity in HIV/TB patients. METHODS: 213 patients were randomly divide into 3 groups, including group A was given sequential therapy of reduced glutathione, group B sequential therapy of Compound glycyrrhizin and group C sequential therapy of intravenous dripping of reduced glutathione and oral dose of Compound glycyrrhizin. Therapeutic efficacies and adverse drug reactions were observed in 3 groups, and cost-effectiveness of 3 schemes were analyzed by pharmacoeconomics. RESULTS: The costs for the 3 treatment schemes were 1 221.0 yuan, 1 076.5 yuan and 960.7 yuan respectively; the incidences of adverse drug reactions were 50.7% , 40.8% and 43.7%respectively (P>0.05) ; the effective rates were 94.4% ,85.9% and 90.1% (P>0.05), respectively; there was no significant difference in the effective rates of 3 therapeutic schemes in the treatment of antituberculosis drug-induced hepatotoxicity in HIV/TB patients (P>0.05) ; the cost-effectiveness ratio were 12.9, 12.5 and 10.7(P< 0.05). CONCLUSION: Compared with scheme A and scheme B, schemes C is the preferable one for drug-induced hepatic injury in HIV/TB patients.%目的:探讨3种不同治疗方案用于治疗人类免疫缺陷病毒合并结核杆菌(HIV/TB)感染患者抗结核药物性肝损伤的成本与效果.方法:将213例患者随机均分成A、B、C组,A组应用还原型谷胱甘肽静脉滴注+口服序贯治疗,B组应用复方甘草酸苷静脉滴注+口服序贯治疗,C组应用还原型谷胱甘肽静脉滴注+复方甘草酸苷口服序贯治疗,观察3组疗效和不良反应,并运用药物经济学方法分析其成本-效果.结果:3种药物治疗方案成本分别为1 221.0、1 076.5、960.7元(P＞0.05)；有效率分别为94.4％、85.9％、90.1％ (P＞0.05)；不良反应发生率分别为50.7％、40.8％、43.7％ (P＞0.05)；成本-效果比分别为12.9、12.5、10.7(P＜0.05).结论:与A、B方案比较,C方案治疗HIV/TB感染患者抗结核药物性肝损伤疗效相当,但经济性较好.
展开▼
